J. Mouscadet

发表

Relationship between the Oligomeric Status of HIV-1 Integrase on DNA and Enzymatic Activity*

E. Guiot, Kévin Carayon, O. Delelis, 2006, Journal of Biological Chemistry.

Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.

F. Bailly, J. Mouscadet, Z. Debyser, 2008, Journal of medicinal chemistry.

HIV-1 integrase inhibition of biscoumarin analogues.

J. Mouscadet, Chang-Xiao Su, Chih-Chia Chiang, 2006, Chemical & pharmaceutical bulletin.

Flavin-oligonucleotide conjugates: sequence specific photocleavage of DNA

M. Fontecave, J. Mouscadet, J. Décout, 1998 .

HIV‐1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations

V. Calvez, O. Delelis, J. Mouscadet, 2009, Journal of molecular recognition : JMR.

Kinetic study of the HIV−1 DNA 3′‐end processing

M. Gottikh, J. Mouscadet, J. Brochon, 2006, The FEBS journal.

Synthesis of benzo-, pyrido-, thieno- and imidazo-fused N-hydroxy-4-oxopyrimidine-2-carboxylic acid derivatives

J. Mouscadet, J. Vilarrasa, L. Bosch, 2011 .

Development of Styrylquinoline Integrase Inhibitors

J. Mouscadet, E. Deprez, D. Desmaële, 2011 .

Alternate Strand DNA Triple Helix-mediated Inhibition of HIV-1 U5 Long Terminal Repeat Integration in Vitro(*)

D. Cherny, J. Mouscadet, M. Bouziane, 1996, The Journal of Biological Chemistry.

Exogenous nucleosides promote the completion of MoMLV DNA synthesis in G0-arrested Balb c/3T3 fibroblasts.

J. Mouscadet, C. Auclair, F. Subra, 1994, Virology.

A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain

Kévin Carayon, F. Simon, J. Mouscadet, 2010, Nucleic acids research.

Branched oligonucleotide‐intercalator conjugate forming a parallel stranded structure inhibits HIV‐1 integrase

J. Mouscadet, M. Pinskaya, E. Romanova, 1999, FEBS letters.

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

V. Calvez, C. Katlama, O. Delelis, 2009, The Journal of antimicrobial chemotherapy.

DNA binding induces dissociation of the multimeric form of HIV-1 integrase: A time-resolved fluorescence anisotropy study

P. Tauc, J. Mouscadet, J. Brochon, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and antiviral properties of some polyphenols related to Salvia genus.

F. Bailly, J. Mouscadet, Z. Debyser, 2008, Bioorganic & medicinal chemistry letters.

Insight into the Integrase-DNA Recognition Mechanism

E. Guiot, Kévin Carayon, O. Delelis, 2008, Journal of Biological Chemistry.

Probing of HIV-1 Integrase/DNA Interactions Using Novel Analogs of Viral DNA*

E. Zubin, M. Gottikh, J. Mouscadet, 2006, Journal of Biological Chemistry.

Design, synthesis, and anti-integrase activity of catechol-DKA hybrids.

F. Bailly, J. Mouscadet, P. Cotelle, 2006, Bioorganic & medicinal chemistry.

Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase.

P. Tauc, J. Mouscadet, J. Brochon, 2000, Biochemistry.

Disulfide-Linked Integrase Oligomers Involving C280 Residues Are Formed In Vitro and In Vivo but Are Not Essential for Human Immunodeficiency Virus Replication

J. Mouscadet, J. Brochon, E. Deprez, 2003, Journal of Virology.

Inhibition of the in vitro integration of Moloney murine leukemia virus DNA by the DNA minor groove binder netropsin.

J. Mouscadet, C. Auclair, F. Subra, 1994, Biochemical pharmacology.

Inhibition of the Moloney murine leukemia virus cycle at a post reverse transcriptional step by the netropsin-intercalating hybrid molecule netropsin-oxazolopyridocarbazole.

J. Mouscadet, M. Lavignon, C. Auclair, 1993, Biochemical pharmacology.

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

V. Calvez, C. Katlama, O. Delelis, 2009, Antiviral therapy.

Ethyl malonate amides: a diketo acid offspring fragment for HIV integrase inhibition.

J. Polanski, É. Laine, J. Mouscadet, 2011, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections.

J. Mouscadet, A. Fournet, R. Hocquemiller, 2003, Bioorganic & medicinal chemistry.

Long-Lasting Persistence of Integrase Resistance Mutations in HIV-2-Infected Patients after Raltegravir Withdrawal

C. Charpentier, F. Brun-Vézinet, O. Delelis, 2011, Antiviral therapy.

Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.

F. Bailly, J. Mouscadet, N. Pommery, 2008, European journal of medicinal chemistry.

Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle.

J. Mouscadet, C. Auclair, F. Subra, 1999, Journal of molecular biology.

The engagement of activating FcγRs inhibits primate lentivirus replication in human macrophages

F. Barré-Sinoussi, J. Mouscadet, A. Sáez-Cirión, 2007, The Journal of Immunology.

Optimization of alternate-strand triple helix formation at the 5"-TpA-3" and 5"-ApT-3" junctions.

J. Mouscadet, P. Brodin, C. Auclair, 1999, Nucleic acids research.

Inhibition of the Human Immunodeficiency Virus Type 1 DNA Integration by Modified Oligonucleotides

M. Gottikh, J. Mouscadet, M. Pinskaya, 2000, Molecular Biology.

Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition.

C. Van Lint, J. Wouters, J. Mouscadet, 2011, European journal of medicinal chemistry.

Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor.

C. Van Lint, J. Wouters, J. Mouscadet, 2009, Bioorganic & medicinal chemistry letters.

Raltegravir: molecular basis of its mechanism of action

J. Mouscadet, L. Tchertanov, 2009, European journal of medical research.

Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors

J. Mouscadet, D. Desmaële, 2010, Molecules.

Impact of the Ku Complex on HIV-1 Expression and Latency

I. Vitale, P. Dessen, O. Delelis, 2013, PloS one.

Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers.

J. Mouscadet, M. S. Benleulmi, R. Maroun, 2001, Biochemistry.

Chemical modification of coumarin dimer and HIV-1 integrase inhibitory activity.

J. Mouscadet, L. Hsu, H. Leh, 2002, Chemical & pharmaceutical bulletin.

Selective binding to polynucleotides of the hybrid intercalating groove binder bis(pyrrolecarboxamide)-oxazolopyridocarbazole: a molecular modeling study.

J. Mouscadet, C. Auclair, J. Sun, 1994, Biochemistry.

HIV-1 replication inhibitors of the styrylquinoline class: introduction of an additional carboxyl group at the C-5 position of the quinoline

J. Mouscadet, D. Desmaële, J. D'angelo, 2005 .

New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity.

J. Mouscadet, D. Desmaële, J. D'angelo, 2005, Bioorganic & medicinal chemistry letters.

Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents

C. Vita, J. Mouscadet, E. Deprez, 2004, Journal of Virology.

Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity.

J. Mouscadet, M. Le Bret, D. Desmaële, 2004, Bioorganic & medicinal chemistry letters.

Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.

Sophie Barbe, Christian Auclair, Jean-François Mouscadet, 2004, Molecular pharmacology.

Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines.

Johann Gasteiger, Jaroslaw Polanski, Rafal Gieleciak, 2002, Journal of medicinal chemistry.

HIV-1 replication inhibitors of the styrylquinoline class: incorporation of a masked diketo acid pharmacophore

J. Mouscadet, M. L. Bret, D. Desmaële, 2001 .

Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives.

M Le Bret, J. Mouscadet, M. Le Bret, 2000, Journal of medicinal chemistry.

Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture.

M Le Bret, J. Mouscadet, M. Le Bret, 2000, Journal of medicinal chemistry.

Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.

J. Mouscadet, D. Desmaële, J. D'angelo, 1998, Journal of medicinal chemistry.

Synthesis and HIV-1 integrase inhibition of novel bis- or tetra-coumarin analogues.

J. Mouscadet, Chih-Chia Chiang, Hou-Jen Tsai, 2007, Chemical & pharmaceutical bulletin.

Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase, RNase H, and Integrase Activities by Hydroxytropolones

C. Isel, J. Mouscadet, R. Marquet, 2005, Antimicrobial Agents and Chemotherapy.

Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors.

J. Polanski, J. Mouscadet, M. Le Bret, 2006, Bioorganic & medicinal chemistry letters.

Target recognition by catechols and beta-ketoenols: potential contribution of hydrogen bonding and Mn/Mg chelation to HIV-1 integrase inhibition.

J. Mouscadet, L. Tchertanov, 2007, Journal of medicinal chemistry.

HIV-1 integrase: the next target for AIDS therapy?

J. Mouscadet, D. Desmaële, J. D'angelo, 2001, Pathologie-biologie.

Synthesis and antiviral properties of some polyphenols related to Salvia genus.

F. Bailly, J. Mouscadet, Z. Debyser, 2008, Bioorganic & medicinal chemistry letters.

Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.

J. Mouscadet, D. Desmaële, J. D'angelo, 1998, Journal of medicinal chemistry.

Reaction of rosmarinic acid with nitrite ions in acidic conditions: discovery of nitro- and dinitrorosmarinic acids as new anti-HIV-1 agents.

F. Bailly, J. Mouscadet, Z. Debyser, 2008, Journal of medicinal chemistry.

Pyridoxine hydroxamic acids as novel HIV-integrase inhibitors.

O. Delelis, J. Mouscadet, S. Garde, 2016, Bioorganic & medicinal chemistry letters.

Synthesis and HIV-1 integrase inhibitory activities of caffeic acid dimers derived from Salvia officinalis.

F. Bailly, J. Mouscadet, P. Cotelle, 2005, Bioorganic & medicinal chemistry letters.

Spectroscopy and photophysics of styrylquinoline-type HIV-1 integrase inhibitors and its oxidized forms studied by steady state and time resolved absorption and fluorescence

M. Fontaine‐Aupart, P. Tauc, J. Mouscadet, 2001 .

Ku Represses the HIV-1 Transcription

L. Jeanson, J. Mouscadet, 2002, The Journal of Biological Chemistry.

Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo

Luba Tchertanov, Vincent Calvez, V. Calvez, 2009, Antimicrobial Agents and Chemotherapy.

Synthesis and anti-HIV-1 integrase activity of modified dinucleotides.

J. Mouscadet, H. Meudal, M. Chassignol, 2009, European journal of medicinal chemistry.

Investigation of Novel Lipid-Functionalized PNA Monomers as Potential HIV-1 Non-Nucleoside Reverse Transcriptase and/or Integrase Inhibitors

G. Maga, J. Mouscadet, N. Howarth, 2007, Nucleosides, nucleotides & nucleic acids.

Triple helix formation with short oligonucleotide-intercalator conjugates matching the HIV-1 U3 LTR end sequence.

J. Mouscadet, M. Le Bret, C. Auclair, 1994, Biochemistry.

Resistance to HIV-1 integrase inhibitors: A structural perspective.

Luba Tchertanov, Jean-François Mouscadet, O. Delelis, 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

Luba Tchertanov, Vincent Calvez, Frédéric Subra, 2008, Nucleic acids research.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Luba Tchertanov, Vincent Calvez, Christine Katlama, 2008, Antimicrobial Agents and Chemotherapy.

Integrase and integration: biochemical activities of HIV-1 integrase

A. Saïb, Kévin Carayon, O. Delelis, 2008, Retrovirology.

Structure-Activity Relationship Studies of HIV-1 Integrase Oligonucleotide Inhibitors.

M. Gottikh, J. Mouscadet, T. Zatsepin, 2011, ACS medicinal chemistry letters.

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.

M. Buckle, J. Mouscadet, M. Pinskaya, 2002, Biochemistry.

6-OXOCYTIDINE CONTAINING OLIGONUCLEOTIDES INHIBIT THE HIV-1 INTEGRASE IN VITRO

J. Mouscadet, M. Pinskaya, E. Romanova, 2001, Nucleosides, nucleotides & nucleic acids.

Triplex-mediated inhibition of HIV DNA integration in vitro.

J. Mouscadet, C. Auclair, F. Subra, 1994, The Journal of biological chemistry.

Interactions of the C-terminus of viral protein R with nucleic acids are modulated by its N-terminus.

B. Roques, J. Mouscadet, H. Rocquigny, 2000, European journal of biochemistry.

A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles

O. Delelis, J. Mouscadet, C. Petit, 2005, Retrovirology.

Effect of Ku80 depletion on the preintegrative steps of HIV-1 replication in human cells.

J. Bourhis, L. Jeanson, J. Mouscadet, 2002, Virology.

Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro

B. Roques, J. Darlix, J. Mouscadet, 1997, Journal of virology.

Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2010, Antimicrobial Agents and Chemotherapy.

INSIGHT INTO THE INTEGRASE-DNA RECOGNITION MECHANISM: A SPECIFIC DNA-BINDING MODE REVEALED BY AN ENZYMATICALLY LABELED INTEGRASE*

E. Guiot, Kévin Carayon, O. Delelis, 2008 .

Efficient and Specific Internal Cleavage of a Retroviral Palindromic DNA Sequence by Tetrameric HIV-1 Integrase

O. Delelis, J. Mouscadet, E. Deprez, 2007, PloS one.

HIV-1 integrase catalytic core: molecular dynamics and simulated fluorescence decays.

J. Mouscadet, J. Brochon, E. Deprez, 2001, Biophysical journal.

Interactions of HIV-1 DNA Heterocyclic Bases with Viral Integrase

M. Gottikh, J. Mouscadet, J. Brochon, 2004, Molecular Biology.

HIV-1 integrase can process a 3'-end crosslinked substrate.

E. Zubin, M. Gottikh, J. Mouscadet, 2004, European journal of biochemistry.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

C. Charpentier, O. Delelis, J. Mouscadet, 2011, Retrovirology.

Biochemical properties of the xenotropic murine leukemia virus-related virus integrase.

M. Buckle, O. Delelis, J. Mouscadet, 2014, Biochimie.

Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection

G. Kroemer, R. Casetti, J. Kanellopoulos, 2011, The Journal of experimental medicine.

New HIV‐1 Replication Inhibitors of the Styryquinoline Class Bearing Aroyl/Acyl Groups at the C‐7 Position: Synthesis and Biological Activity.

J. Mouscadet, D. Desmaële, J. D'angelo, 2005 .

Styrylquinolines, Integrase Inhibitors Acting Prior to Integration: a New Mechanism of Action for Anti-Integrase Agents

C. Vita, J. Mouscadet, E. Deprez, 2004, Journal of Virology.

HIV-1 Replication Inhibitors of the Styrylquinoline Class: Incorporation of a Masked Diketo Acid Pharmacophore.

J. Mouscadet, M. L. Bret, D. Desmaële, 2002 .

Nuclear Import of HIV-1 Integrase Is Inhibited in Vitro by Styrylquinoline Derivatives

J. Mouscadet, C. Dargemont, A. Mousnier, 2004, Molecular Pharmacology.

Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core.

M Le Bret, J. Mouscadet, M. Le Bret, 2000, Acta biochimica Polonica.

Ku80 Participates in the Targeting of Retroviral Transgenes to the Chromatin of CHO Cells

Elvire Guiot, Laurence Jeanson-Leh, E. Guiot, 2007, Journal of Virology.

Oligomeric states of the HIV-1 integrase as measured by time-resolved fluorescence anisotropy.

P. Tauc, J. Mouscadet, J. Brochon, 2000, Biochemistry.

Structural basis for HIV‐1 DNA integration in the human genome, role of the LEDGF/P75 cofactor

D. Moras, R. Benarous, M. Gottikh, 2009, The EMBO journal.

A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA.

J. Gatell, R. Gorelick, E. Le Cam, 2013, Virus research.

The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1

J. Mouscadet, O. Schwartz, B. Gay, 2003, Journal of Virology.

The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA.

B. Roques, P. Tauc, J. Mouscadet, 2003, Nucleic acids research.

Inhibition of Early Steps of HIV-1 Replication by SNF5/Ini1*

J. Rain, R. Benarous, O. Delelis, 2006, Journal of Biological Chemistry.

3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors.

L. Galluzzi, J. Mouscadet, G. Manic, 2012, Human gene therapy methods.

Structural basis for HIV-1 DNA integration in the human genome

D. Moras, R. Benarous, M. Gottikh, 2009, Retrovirology.

Synthesis and HIV-1 integrase inhibitory activities of catechol and bis-catechol derivatives.

L. Jeanson, J. Mouscadet, P. Cotelle, 2001, Bioorganic & medicinal chemistry letters.

The total synthesis of fukiic acid, an HIV-1 integrase inhibitor.

F. Bailly, J. Mouscadet, Z. Debyser, 2008, European journal of medicinal chemistry.

5-Hydroxy-6-Quinaldic Acid as a Novel Molecular Scaffold for HIV-1 Integrase Inhibitors

Jaroslaw Polanski, Marc Le Bret, Robert Musiol, 2006 .

Simple criterion for selection of flavonoid compounds with anti-HIV activity.

J. Mouscadet, N. Veljkovic, S. Glišić, 2007, Bioorganic & medicinal chemistry letters.

Inhibition of HIV Integrase by 4-Hydroxycoumarin Dimer Bearing Aniline Mustard Moiety

J. Mouscadet, L. Hsu, H. Leh, 2001 .

Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction.

J. Mouscadet, C. Auclair, F. Subra, 1993, Archives of biochemistry and biophysics.

Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction.

J. Mouscadet, C. Auclair, F. Subra, 1993, Biochemical and biophysical research communications.

Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site.

F. Bailly, H. Vezin, J. Mouscadet, 2004, Journal of medicinal chemistry.

New 2-arylnaphthalenediols and triol inhibitors of HIV-1 integrase--discovery of a new polyhydroxylated antiviral agent.

F. Bailly, H. Vezin, J. Mouscadet, 2010, Bioorganic & medicinal chemistry.

Quantitative in vitro assay for human immunodeficiency virus deoxyribonucleic acid integration.

J. Mouscadet, C. Auclair, F. Subra, 1993, Archives of biochemistry and biophysics.

Fragment Based Approach for the Investigation of HIV-1 Integrase Inhibition

J. Polanski, J. Mouscadet, M. L. Bret, 2007 .

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors

V. Calvez, É. Laine, J. Mouscadet, 2012, Advances in virology.

Impact of Y 143 HIV-1 integrase mutations on resistance to Raltegravir in vitro and in vivo

Luba Tchertanov, Vincent Calvez, Frédéric Subra, 2009 .

The G 140 S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q 148 H mutation

Luba Tchertanov, Vincent Calvez, Jean-François Mouscadet, 2009 .

HIV-1 integrase complexes with DNA dissociate in the presence of short oligonucleotides conjugated to acridine.

J. Mouscadet, J. Brochon, E. Deprez, 2004, Biochemistry.

The Engagement of Activating FcγRs Inhibits Primate Lentivirus Replication in Human Macrophages1

J. Mouscadet, A. Sáez-Cirión, F. Barré-Sinoussi, 2006, The Journal of Immunology.

MacrophagesLentivirus Replication in Human Rs Inhibits γ The Engagement of Activating Fc

J. Mouscadet, B. Iannascoli, F. Herschke, 2013 .

Structural effects of amino acid variations between B and CRF02‐AG HIV‐1 integrases

O. Traoré, V. Calvez, C. Katlama, 2008, Journal of medical virology.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

V. Calvez, C. Katlama, O. Delelis, 2008, Antimicrobial Agents and Chemotherapy.

HIV-1 integrase catalytic core: molecular dynamics and simulated fluorescence decays.

J. Mouscadet, J. Brochon, M. L. Bret, 2001, Biophysical journal.

Structural effects of amino acid variations between B and CRF02‐AG HIV‐1 integrases

O. Traoré, V. Calvez, C. Katlama, 2008, Journal of Medical Virology.